文献速递乳腺癌放疗放疗物理与技术

乳腺癌辅助放疗的成本效益权衡:系统综述

Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?
PubMed 文献 · Radiother Oncol · 2017-11-23

结果显示大分割较常规分割更具成本效益,部分乳腺照射结果不一致,术中或外照射在有利风险组可能最经济,但全乳照射健康效果更优。

要点

  • 大分割放疗相比常规分割具有成本效益。
  • 部分乳腺照射的成本效益结果尚不明确。
  • 术中或外照射在有利风险组可能最具成本效益。

核心结论

  • 大分割可作为乳腺癌辅助放疗新策略的最相关比较对象。
  • 在非常有利的亚组中,省略放疗是值得考虑的替代方案,尤其对于部分乳腺技术。

研究设计与样本

  • 基于2000年1月1日至2016年10月30日的系统文献综述,纳入比较不同辅助乳腺放疗方法的成本比较和成本效果分析。

主要发现

  • 常规分割和调强、组织间或腔内技术是重要的成本驱动因素。
  • 美国的报销费用最高,但可能高估真实成本。
  • 大分割相比常规分割具有成本效益,部分乳腺照射结果较不一致。
  • 术中及外照射方法似乎对有利风险组最具成本效益,但全乳照射在健康效果上更优,省略放疗在成本上更优。

关键数值与推荐

  • 成本转换为2016年欧元,每QALY成本汇总于成本效果平面。

临床怎么用

  • 健康经济学证据可指导决策,以制定量身定制的策略,在正确适应证中分配效果与效率最优的治疗。

局限性

  • 成本比较和成本效果分析的可比性受临床和经济环境 variability 的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A series of health economic evaluations (HEE) has analysed the efficiency of new fractionation schedules and techniques for adjuvant breast radiotherapy. This overview assembles the available evidence and evaluates to what extent HEE-results can be compared. METHODS: Based on a systematic literature review of HEEs from 1/1/2000 to 30/10/2016, all cost comparison (CC) and cost-effectiveness analyses (CEA) comparing different adjuvant breast radiotherapy approaches were analysed. Costs were extracted and converted to Euro 2016 and costs per QALY were summarized in cost-effectiveness planes. RESULTS: Twenty-four publications are withheld, comparing different fractionation schedules and/or irradiation techniques or evaluating the value of adding radiotherapy. Normofractionation and intensity-modulated, interstitial or intraluminal techniques are important cost-drivers. Highest reimbursements are observed in the US, but may overestimate the real cost. Hypofractionation is cost-effective compared to normofractionation, the results of partial breast irradiation are less unequivocal. Intra-operative and external beam approaches seem the most cost-effective for favourable risk groups, but whole breast irradiation is superior in terms of health effect and omission of radiotherapy in terms of costs. CONCLUSION: Hypofractionation may be considered the most relevant comparator for new strategies in adjuvant breast radiotherapy, with omission of radiotherapy as an interesting alternative in the very favourable subcategories, especially for partial breast techniques. Although comparison of CC and CEA is hampered by the variability in clinical and economic settings, HEE-based evidence can guide decision-making to tailor-made strategies, allocating the optimal treatment in terms of effectiveness as well as efficiency to the right indication.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Monten C, Lievens Y. Adjuvant breast radiotherapy: How to trade-off cost and effectiveness? Radiother Oncol. 2017. PMID: 29174721. doi:10.1016/j.radonc.2017.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。